Volume 20, Number 3—March 2014
Research
Hendra Virus Vaccine, a One Health Approach to Protecting Horse, Human, and Environmental Health
Table 2
Quantitative reverse transcription PCR detection of Hendra virus N gene in samples collected daily from control horses*
Horse no., sample | log10 relative copy number of Hendra virus N RNA, dpc |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | |
1† | ||||||||||
Blood | − | − | − | − | − | −0.2 | 1.4 | 1.7 | ||
Urine | − | − | − | − | − | − | −0.8 | 1.1 | ||
Feces | − | − | − | − | − | − | − | −0.7 | ||
Nasal swab | − | − | −0.3 | −0.2 | 1.4 | 1.6 | 1.4 | 1.7 | ||
Oral swab |
− |
− |
− |
− |
− |
−0.1 |
1.3 |
1.3 |
||
2‡ | ||||||||||
Blood | − | − | − | − | 0.5 | 2.6 | 3.0 | |||
Urine | − | − | − | − | − | 0.3 | 1.7 | |||
Feces | − | − | − | − | − | −0.05 | 2.0 | |||
Nasal swab | − | − | 1.2 | 2.0 | 1.6 | 3.5 | 2.5 | |||
Oral swab |
− |
− |
− |
− |
− |
0.4 |
1.5 |
|||
3‡ | ||||||||||
Blood | − | − | − | − | − | − | 1.5 | 2.8 | 2.9 | 3.4 |
Urine | − | − | − | − | − | − | − | 1.8 | 1.7 | 3.0 |
Feces | − | − | − | − | − | − | − | 1.5 | 1.7 | 2.1 |
Nasal swab | − | − | 1.7 | 2.5 | 1.2 | 2.4 | 3.0 | 3.8 | 3.7 | 2.0 |
Oral swab |
− |
− |
− |
− |
− |
− |
− |
1.9 |
1.9 |
2.3 |
4‡ | ||||||||||
Blood | − | − | − | − | − | 0.1 | 1.9 | 2.5 | 3.0 | |
Urine | − | − | − | − | − | − | 0.07 | 0.5 | 2.1 | |
Feces | − | − | − | − | − | − | 1.3 | 2.4 | 2.1 | |
Nasal swab | − | − | 0.3 | − | − | − | − | 1.6 | 2.5 | |
Oral swab | − | − | − | − | − | − | 0.2 | 1.2 | 1.6 |
*Duplicate samples were obtained and tested by reverse transcription PCR. Cycle threshold values were converted to relative copy numbers by using a standard curve of a sample with a known copy number. dpc, days after challenge. − indicates a negative result; blank space indicates no sample was tested.
†N gene data for horse 1 was obtained from the current study.
‡N gene data for horses 2–4 are unpublished data from a previous study (6).
References
- Halpin K, Hyatt AD, Fogarty R, Middleton D, Bingham J, Epstein JH, Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission. Am J Trop Med Hyg. 2011;85:946–51. DOIPubMedGoogle Scholar
- Playford EG, McCall B, Smith G, Slinko V, Allen G, Smith I, Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008. Emerg Infect Dis. 2010;16:219–23. DOIPubMedGoogle Scholar
- Field H, Crameri G, Kung NY, Wang LF. Ecological aspects of Hendra virus. Curr Top Microbiol Immunol. 2012;359:11–23 . DOIPubMedGoogle Scholar
- Williamson MM, Hooper PT, Selleck PW, Gleeson LJ, Daniels PW, Westbury HA, Transmission studies of Hendra virus (equine morbillivirus) in fruit bats, horses and cats. Aust Vet J. 1998;76:813–8 . DOIPubMedGoogle Scholar
- Weingartl HM, Berhane Y, Czub M. Animal models of henipavirus infection. Vet J. 2009;181:211–20 . DOIPubMedGoogle Scholar
- Middleton DJ, Weingartl HM. Henipaviruses in their natural hosts. Curr Top Microbiol Immunol. 2012;359:105–21. DOIPubMedGoogle Scholar
- Degeling C, Kerridge I. Hendra in the news: public policy meets public morality in times of zoonotic uncertainty. Soc Sci Med. 2013;82:156–63. DOIPubMedGoogle Scholar
- Mendez DH, Judd J, Speare R. Unexpected result of Hendra virus outbreaks for veterinarians, Queensland, Australia. Emerg Infect Dis. 2012;18:83–5. DOIPubMedGoogle Scholar
- Mahalingam S, Herrero LJ, Playford EG, Spann K, Herring B, Rolph MS, Hendra virus: an emerging paramyxovirus in Australia. Lancet Infect Dis. 2012;12:799–807. DOIPubMedGoogle Scholar
- Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman J, Global trends in emerging infectious diseases. Nature. 2008;451:990–3. DOIPubMedGoogle Scholar
- Mazet JA, Clifford DL, Coppolillo PB, Deolalikar AB, Erickson JD, Kazwala RR. “One Health” approach to address emerging zoonoses: the Hali Project in Tanzania. PLoS Med. 2009;6:e1000190. DOIPubMedGoogle Scholar
- Abraham G, Muschialli J, Middleton D. Animal experimentation in level 4 facilities. In: Richmond JY, editor. Anthology of biosafety: BSL-4 laboratories. Mundelein (IL): American Biological Safety Association; 2002. p. 343–59.
- Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, Patch JR, Receptor binding, fusion inhibition and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol. 2005;79:6690–702. DOIPubMedGoogle Scholar
- Pallister J, Middleton D, Wang LF, Klein R, Haining J, Robinson R, A recombinant Hendra virus G glycoprotein–based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine. 2011;29:5623–30. DOIPubMedGoogle Scholar
- Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, Russell G, Feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol. 2006;80:12293–302. DOIPubMedGoogle Scholar
- McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, Middleton D, A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine. 2008;26:3842–52. DOIPubMedGoogle Scholar
- Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, LaCasse R, A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med. 2012;4:146ra07. PMID: 22875827
- Steffen DL, Xu K, Nikolov DB, Broder CC. Henipavirus mediated membrane fusion, virus entry and targeted therapeutics. Viruses. 2012;4:280–308. DOIPubMedGoogle Scholar
- Broder C, Geisbert T, Xu K, Nikolov D, Wang L-F, Middleton D, Immunization strategies against henipaviruses. In: Lee B, Rota PA, editors. Henipavirus. Berlin: Springer; 2012. p. 197–223.
- Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. PLoS Pathog. 2009;5:e1000642. DOIPubMedGoogle Scholar
- Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, Geisbert JB, A neutralizing human monoclonal antibody protects African green monkeys from Hendra virus challenge. Sci Transl Med. 2011;3:105ra3. PMID: 22013123
- Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P, Nipah virus: vaccination and passive protection studies in a hamster model. J Virol. 2004;78:834–40. DOIPubMedGoogle Scholar
- Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MC, Deubel V, Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol. 2006;80:1972–8. DOIPubMedGoogle Scholar
- Guillaume V, Wong KT, Looi RY, Georges-Courbot MC, Barrot L, Buckland R, Acute Hendra virus infection: analysis of the pathogenesis and passive antibody protection in the hamster model. Virology. 2009;387:459–65. DOIPubMedGoogle Scholar
- Graham BS, Crowe JE. Immunization against viral diseases. In: Knipe DM, Griffin DE, Lamb RA, Straus SE, Howley PM, Martin MA, et al., editors. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 487–538.
- Wolinsky JS, Waxham MN, Server AC. Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis. J Virol. 1985;53:727–34 .PubMedGoogle Scholar
- Plotkin SA. Vaccination against the major infectious diseases. C R Acad Sci III. 1999;322:943–51. DOIPubMedGoogle Scholar
- Snoy PJ. Establishing efficacy of human products using animals: the US Food and Drug Administration's “animal rule.”. Vet Pathol. 2010;47:774–8. DOIPubMedGoogle Scholar
- Breed AC, Yu M, Barr JA, Crameri G, Thalmann CM, Wang LF. Prevalence of henipavirus and rubulavirus antibodies in pteropid bats, Papua New Guinea. Emerg Infect Dis. 2010;16:1997–9. DOIPubMedGoogle Scholar
- Drexler JF, Corman VM, Gloza-Rausch F, Seebens A, Annan A, Ipsen A, Henipavirus RNA in African bats. PLoS ONE. 2009;4:e6367. DOIPubMedGoogle Scholar
- Epstein JH, Prakash V, Smith CS, Daszak P, McLaughlin AB, Meehan G, Henipavirus infection in fruit bats (Pteropus giganteus), India. Emerg Infect Dis. 2008;14:1309–11. DOIPubMedGoogle Scholar
1These authors contributed equally to this article.